Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bioscrip Inc. (BIOS): Billionaire Mario Gabelli’s GAMCO Investors Slightly Lowers Its Stake

Page 1 of 16

Billionaire Mario Gabelli‘s GAMCO Investors recently filed an amended Form 13D with the US Securities and Exchange Commission, in which it reported slightly lowering its stake in Bioscrip Inc. (NASDAQ:BIOS). The fund, together with its affiliates, holds 15.53 million shares of the company, which amass 13.19% of the float, while GAMCO solely owns 866,402 shares or 0.74% of the outstanding stock. According to its 13F filing for the June 30 reporting period, GAMCO held 904,402 Bioscrip common shares.

Bioscrip Inc. (NASDAQ:BIOS) is a company that provides infusion and home care management solutions, working with healthcare facilities and medical professionals. Over the past 12 months, the company’s shares have gained a robust 78.57%. For the second quarter of 2016, Bioscrip reported a loss per share of $0.14, and revenue of $232.46 million, compared to a loss per share of $3.63 and revenue of $246.9 million for the corresponding quarter of 2015.


According to Insider Monkey’s hedge fund database, 23 investors in it reported having long positions in Bioscrip Inc. (NASDAQ:BIOS) as of the end of June, up by ten from the end of the previous quarter. Among the bullish investors were Stephen Dubois’ Camber Capital Management, which held a position valued at $25.96 million, Ric Dillon’s Diamond Hill Capital, with a position worth $13.56 million, Phil Frohlich’s Prescott Group Capital Management, and Ken Griffin’s Citadel Investment Group.

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!

Some of the investors who initiated new positions in Bioscrip Inc. (NASDAQ:BIOS) during the June quarter included Conan Laughlin’s North Tide Capital, which acquired the largest position, worth $21.68 million. The second-biggest stake in the company was initiated by James E. Flynn’s Deerfield Management, which had $7.62 million invested in the stock by June 30. Other bullish investors with new positions contained Anand Parekh’s Alyeska Investment Group, Andrew Feldstein and Stephen Siderow’s Blue Mountain Capital, and Andrew Goldman’s Seven Locks Capital Management.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Gabelli Funds 13,785,843 13,785,843 13,785,843 11.71%
GAMCO Asset Management Inc. I.D. No. 13-40445 816,402 866,402 866,402 0.74%
Teton Advisors, Inc. I.D. No. 13-4008049 872,000 872,000 872,000 0.74%
GGCP, Inc. I.D. No. 13-3056041 0.00%
GAMCO Investors, Inc. I.D. No. 13-400786 2,700 2,700 2,700 0.00%
Associated Capital Group, Inc. I.D. No. 47-3965991 Check the appropriate box if a member of a group (SEE INSTRUCTIONS) (a) (b) 0.00%
Mario J. Gabelli 0.00%

Mario Gabelli
Mario Gabelli
GAMCO Investors

Page 1 of 16 – SEC Filing

Washington, D.C. 20549
Under the Securities Exchange Act of 1934 (Amendment No. 15)
BioScrip, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
(CUSIP Number)
David Goldman
GAMCO Investors, Inc.
One Corporate Center
Rye, New York 10580-1435
(914) 921-5000
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
______________________ October 11, 2016________________________
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box .

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!
Page 1 of 16

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!